COPA syndrome is a devastating, rare genetic disorder that disrupts the immune system. It leads to inflammation of organs such as the lungs and kidneys, as well as inflammation of the joints. These tissues are particularly vulnerable to the gene mutations linked to COPA syndrome. This inflammation occurs because COPA syndrome is an autoimmune disease, which means the body’s immune system mistakenly attacks its own tissue instead of harmful germs. Symptoms often begin during childhood and can include a persistent cough, bloody urine, or joint pain.
Coughing is one of the many symptoms of COPA syndrome
Image Source: PhotoAlto/Frederic Cirou
The disease is caused by mutations of the COPA gene, which normally produces the “alpha” subunit of the COP1 protein. The COP1 protein helps transport proteins between the Golgi apparatus and endoplasmic reticulum, two important structures within human cells. This transport is essential for the cell’s normal processes, including proper production of proteins, as well as the regulation of cellular signaling pathways. Mutations in the COPA gene disrupt this transport system, which eventually leads to dysfunctional proteins that accumulate in the cell, activating the body’s inflammatory response and disrupting the immune system.
Interestingly, not everyone with a mutated COPA gene will develop COPA syndrome. Recent research has provided more information on this unusual phenomenon, where COPA syndrome does not develop in people who have a specific variant of the STING gene known as HAQ-STING. Various studies showed that individuals who had both the COPA mutation and the HAQ-STING variant never developed COPA syndrome and were asymptomatic, suggesting that HAQ-STING somehow protects the body from the negative bodily symptoms of the COPA mutation. Further research found that HAQ-STING produces this protective effect by dampening the activation of inflammatory pathways triggered by COPA mutations.
Naturally, scientists were curious if HAQ-STING could be used as a treatment for COPA syndrome. In one investigation, they took cells from the lungs of a COPA syndrome patient and introduced HAQ-STING into the cells; this was able to restore normal immune system function in the cells.
The gravity of these findings cannot be overstated. Researchers are excited that HAQ-STING might lead to gene therapies that can treat COPA syndrome. Currently, treatment options for COPA syndrome are few and primarily involve immunosuppressive therapies that have limited treatment effectiveness, or in severe cases, organ transplantation that has significant risks. This breakthrough has given hope to all COPA syndrome patients for a better future free of COPA syndrome and all its terrible symptoms. With more research and testing, one day, HAQ-STING-based treatments may be the solution we’ve all been waiting for.
Featured Image Source: Littlewolf1989
